|Bid||101.91 x 1200|
|Ask||101.92 x 800|
|Day's Range||100.86 - 102.30|
|52 Week Range||61.16 - 105.69|
|Beta (5Y Monthly)||0.20|
|PE Ratio (TTM)||41.58|
|Forward Dividend & Yield||1.03 (1.02%)|
|Ex-Dividend Date||Aug 18, 2023|
|1y Target Est||103.96|
Subscribe to Yahoo Finance Plus to view Fair Value for NVO
The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.